Monday, August 7, 2017

Concussion-focused Scythian (TSXV: $SCYB,V) sets market debut

Concussion-focused Scythian  (TSXV: $SCYB,V) sets market debut on the TSX Venture Exchange
The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets.

Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of the company’s outstanding shares, with the rest locked in escrow by the TSX Venture Exchange.

No comments:

Post a Comment